Exelixis Inc.: The Advancement in Early Clinical Pipeline & Other Major Drivers! 

Exelixis’ second quarter 2025 financial results highlight both significant achievements and ongoing challenges for the biotechnology company. Revenue growth and product development are key aspects to consider when forming an investment thesis. In terms of financial performance, Exelixis reported total revenue of $568 million, with the cabozantinib franchise contributing $520 million. This marks a 19% year-over-year increase in the cabozantinib franchise revenue, driven by the U.S. market demand. However, it’s important to note that gross-to-net deductions increased due to higher 340B volume, a factor that can affect net earnings.